regdanvimab   Click here for help

GtoPdb Ligand ID: 11332

Synonyms: CT-P-59 | CT-P59 | Regkirona®
Approved drug
regdanvimab is an approved drug (South Korea & EMA (2021))
Compound class: Antibody
Comment: Regdanvimab (CT-P59) is a recombinant monoclonal antibody against the surface spike protein of SARS-CoV-2 [1]. It was developed by Celltrion. Regdanvimab inhibits SARS-CoV-2 infection via steric hindrance of its binding to human ACE2.
Click here for help
References
1. Kim C, Ryu DK, Lee J, Kim YI, Seo JM, Kim YG, Jeong JH, Kim M, Kim JI, Kim P et al.. (2021)
A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein.
Nat Commun, 12 (1): 288. [PMID:33436577]
2. Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ et al.. (2021)
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
Cochrane Database Syst Rev, 9: CD013825. [PMID:34473343]
3. Syed YY. (2021)
Regdanvimab: First Approval.
Drugs, [Epub ahead of print]. DOI: 10.1007/s40265-021-01626-7 [PMID:34724174]